International Clinical Trial: NeoTRECAMCT-01:A prospective, non-randomized controlled clinical study of SHR-A1811 plus camrelizumab in perioperative combination or sequential chemotherapy for ER(-)/ER(1-10%), HER2-low expressing early or locally advanced breast cancer

Geneva, July 7 -- International Clinical Trials Registry received information related to the study (ChiCTR2600127200) titled 'NeoTRECAMCT-01:A prospective, non-randomized controlled clinical study of SHR-A1811 plus camrelizumab in perioperative combination or sequential chemotherapy for ER(-)/ER(1-10%), HER2-low expressing early or locally advanced breast cancer' on June 26.

Study Type: Interventional study

Study Design: Non randomized control

Primary Sponsor: The First Affiliated Hospital of Xi'an Jiaotong University

Condition: Early or locally advanced breast cancer with low estrogen receptor expression (ER <10%) and low HER2 expression, defined as immunohistochemistry (IHC) 1+, or IHC 2+ with no amplification detected by in situ ...